Advanced

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

Morabito, Fortunato; Bringhen, Sara; Larocca, Alessandra; Wijermans, Pierre; Victoria Mateos, Maria; Gimsing, Peter; Mazzone, Carla; Gottardi, Daniela; Omede, Paola and Zweegman, Sonja, et al. (2014) In American Journal of Hematology 89(4). p.355-362
Abstract
Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9... (More)
Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P<0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P<0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
American Journal of Hematology
volume
89
issue
4
pages
355 - 362
publisher
John Wiley & Sons
external identifiers
  • wos:000334645900002
  • scopus:84897388164
ISSN
0361-8609
DOI
10.1002/ajh.23641
language
English
LU publication?
yes
id
27795074-aa94-4153-a454-2d0f67f614f8 (old id 4559302)
date added to LUP
2014-08-01 07:43:20
date last changed
2017-04-09 03:07:00
@article{27795074-aa94-4153-a454-2d0f67f614f8,
  abstract     = {Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (&gt;65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P=0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P&lt;0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P&lt;0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT. Am. J. Hematol. 89:355-362, 2014. (c) 2013 Wiley Periodicals, Inc.},
  author       = {Morabito, Fortunato and Bringhen, Sara and Larocca, Alessandra and Wijermans, Pierre and Victoria Mateos, Maria and Gimsing, Peter and Mazzone, Carla and Gottardi, Daniela and Omede, Paola and Zweegman, Sonja and Jose Lahuerta, Juan and Zambello, Renato and Musto, Pellegrino and Magarotto, Valeria and Schaafsma, Martijn and Oriol, Albert and Juliusson, Gunnar and Cerrato, Chiara and Catalano, Lucio and Gentile, Massimo and Isabel Turel, Ana and Liberati, Anna Marina and Cavalli, Maide and Rossi, Davide and Passera, Roberto and Rosso, Stefano and Beksac, Meral and Cavo, Michele and Waage, Anders and San Miguel, Jesus and Boccadoro, Mario and Sonneveld, Pieter and Palumbo, Antonio and Offidani, Massimo},
  issn         = {0361-8609},
  language     = {eng},
  number       = {4},
  pages        = {355--362},
  publisher    = {John Wiley & Sons},
  series       = {American Journal of Hematology},
  title        = {Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study},
  url          = {http://dx.doi.org/10.1002/ajh.23641},
  volume       = {89},
  year         = {2014},
}